AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.
AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1 Expression System for mammalian production.
Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time.
Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.
AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1 Expression System for mammalian production.
Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time.
Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.
Location: United States, Washington, Bothell
Employees: 1001-5000
Phone: (425) 485-1900
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | European E... | eeplp.com/ |
Mentions in press and media 27
| Date | Title | Description |
| 09.02.2026 | Pandorum Technologies raises $18M series B led by Protons Corporate | Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global operations. The round was led by Protons Corp... |
| 03.01.2026 | Longmont’s tallest buildings tell the story of a growing city | Getting your Trinity Audio player ready... Longmont is known for its skyline, which features rugged peaks along the Continental Divide, but it also boasts a rich history preserved within its architecture. From historic builds to modern hosp... |
| 19.11.2025 | AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality | AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world’s most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mRNA ther... |
| 16.09.2025 | Wall Street edges back from its record heights | By STAN CHOE, AP Business Writer NEW YORK (AP) — U.S. stocks edged back from their record heights on Tuesday as the countdown ticked toward what Wall Street expects will be the first cut of the year to interest rates by the Federal Reserve.... |
| 16.09.2025 | AGC Biologics to lay off hundreds in Boulder County | AGC Biologics Inc. plans to lay off nearly 300 workers in Boulder County as the contract pharmaceutical manufacturer attempts to sell its factories in Longmont and Boulder. Subscribe to continue reading this article. Already subscribed? To ... |
| 28.11.2024 | Pharmaceutical CDMO Market Size Projected to Reach USD 368.70 Bn by 2034 | The pharmaceutical CDMO market is estimated to grow from USD 197.40 billion in 2025 to approximately USD 368.70 billion by 2034, According to Precedence Research. Ottawa, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The global pharmaceutical CDMO mark... |
| 10.04.2023 | Digital health news, funding round up in the prior week; April 10, 2023 | Digital health investments hit $3.4B; OXOS Medical raised $23M; OpenLoop Health bought Imaging Panda Top Health News Investments in digital health rose to $3.4 billion raised across 132 deals in Q1, up 26% from the $2.7 billion raised in Q4... |
| 18.08.2022 | RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies | “AGC Biologics has an outstanding track record of success in the manufacture of clinical and commercial advanced therapies and an ever-expanding global network to meet the needs of our customers.” - Tim Kelly, CEO, RoosterBio FREDERICK, Md.... |
| 16.08.2022 | RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies | RoosterBio and AGC Biologics Announce Collaboration New partnership delivers clinically proven products and manufacturing processes for advanced therapies SEATTLE, WASHINGTON, UNITED STATES, August 16, 2022 /EINPresswire.com/ -- AGC Biologi... |
| 12.12.2021 | I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project | AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, whil... |
Show more